MX2018014973A - Combinaciones farmaceuticas. - Google Patents

Combinaciones farmaceuticas.

Info

Publication number
MX2018014973A
MX2018014973A MX2018014973A MX2018014973A MX2018014973A MX 2018014973 A MX2018014973 A MX 2018014973A MX 2018014973 A MX2018014973 A MX 2018014973A MX 2018014973 A MX2018014973 A MX 2018014973A MX 2018014973 A MX2018014973 A MX 2018014973A
Authority
MX
Mexico
Prior art keywords
pharmaceutical combinations
pharmaceutically acceptable
acceptable salt
inhibitor
egfr
Prior art date
Application number
MX2018014973A
Other languages
English (en)
Inventor
Alexander Cao Zhu
Caponigro Giordano
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60477982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018014973(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MX2018014973A publication Critical patent/MX2018014973A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En el presente documento se proporcionan combinaciones farmacéuticas que comprenden (a) un inhibidor de B-Raf, o una sal farmacéuticamente aceptable del mismo, (b) al menos un inhibidor de la proteína quinasa activada por mitógenos (MEK), o una sal farmacéuticamente aceptable del mismo, y (c) un inhibidor del receptor del factor de crecimiento epidérmicO (EGFR) o una sal farmacéuticamente aceptable del mismo; y opcionalmente al menos un portador farmacéuticamente aceptable; los métodos para preparar las combinaciones farmacéuticas y los usos de las combinaciones farmacéuticas en el tratamiento de enfermedades proliferativas, como el cáncer.
MX2018014973A 2016-06-03 2017-06-02 Combinaciones farmaceuticas. MX2018014973A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662345389P 2016-06-03 2016-06-03
PCT/US2017/035653 WO2017210538A1 (en) 2016-06-03 2017-06-02 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
MX2018014973A true MX2018014973A (es) 2019-12-18

Family

ID=60477982

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014973A MX2018014973A (es) 2016-06-03 2017-06-02 Combinaciones farmaceuticas.

Country Status (26)

Country Link
US (3) US10485788B2 (es)
EP (1) EP3463345B1 (es)
JP (2) JP6805336B2 (es)
KR (1) KR102439911B1 (es)
CN (1) CN109890386B (es)
AU (1) AU2017275650B2 (es)
BR (1) BR112018074941A2 (es)
CA (1) CA3026361A1 (es)
CL (1) CL2018003421A1 (es)
CO (1) CO2019000010A2 (es)
CR (1) CR20190002A (es)
DK (1) DK3463345T3 (es)
FI (1) FI3463345T3 (es)
HU (1) HUE060653T2 (es)
IL (1) IL263431A (es)
MA (1) MA45187A (es)
MX (1) MX2018014973A (es)
PH (1) PH12018502549A1 (es)
PL (1) PL3463345T3 (es)
PT (1) PT3463345T (es)
RU (1) RU2759669C2 (es)
SG (1) SG11201810793XA (es)
SI (1) SI3463345T1 (es)
UA (1) UA125436C2 (es)
WO (1) WO2017210538A1 (es)
ZA (1) ZA201900019B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE060653T2 (hu) 2016-06-03 2023-04-28 Array Biopharma Inc Gyógyászati kombinációk
CN109715163B (zh) * 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
ES2952265T3 (es) 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
EP4042434A1 (en) * 2019-10-11 2022-08-17 F. Hoffmann-La Roche AG Drug dosage determination devices and methods
US20230060581A1 (en) * 2020-02-10 2023-03-02 Cedars-Sinai Medical Center Method of treating pancreatic cancer
JP7288220B2 (ja) 2021-03-29 2023-06-07 ダイキン工業株式会社 モータ、送風装置、および冷凍装置
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2024126660A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
EP2275102B1 (en) 2002-03-13 2015-07-29 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
PL2324008T3 (pl) 2008-07-24 2012-09-28 Nerviano Medical Sciences Srl 3,4-diarylopirazole jako inhibitory kinazy białkowej
JP5527878B2 (ja) * 2009-07-30 2014-06-25 トムソン ライセンシング 表示装置及び音声出力装置
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
US20140222443A1 (en) * 2011-06-07 2014-08-07 Kathleen Danenberg Molecular profiling for cancer
CN103917236A (zh) * 2011-11-11 2014-07-09 诺华股份有限公司 治疗增生性疾病的方法
LT2782557T (lt) 2011-11-23 2018-12-27 Array Biopharma, Inc. Farmacinės kompozicijos
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
DK2882440T3 (da) 2012-08-07 2019-05-06 Novartis Ag Farmaceutiske kombinationer, der omfatter en b-raf-inhibitor, en egfr-inhibitor og eventuelt en pi3k-alfa-inhibitor
HRP20240033T1 (hr) * 2012-10-19 2024-03-29 Array Biopharma, Inc. Formulacija koja sadrži inhibitor mek
WO2014066606A2 (en) * 2012-10-25 2014-05-01 Glaxosmithkline Llc Combination
CN105209073A (zh) 2013-03-21 2015-12-30 诺华股份有限公司 包含B-Raf抑制剂和第二抑制剂的组合疗法
CN105392763A (zh) 2013-07-18 2016-03-09 株式会社大赛璐 氧化物的制造方法
US20150087279A1 (en) * 2013-09-20 2015-03-26 Better Mousetrap, LLC Mobile accident processing system and method
JP2017500307A (ja) * 2013-12-12 2017-01-05 ノバルティス アーゲー がんの処置のためのトラメチニブ、パニツムマブおよびダブラフェニブの組合せ
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
WO2016155670A1 (zh) * 2015-04-01 2016-10-06 苏州晶云药物科技有限公司 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
US20170027951A1 (en) 2015-07-27 2017-02-02 Southern Research Institute Methods and compositions to treat cancers involving egfr
HUE060653T2 (hu) 2016-06-03 2023-04-28 Array Biopharma Inc Gyógyászati kombinációk

Also Published As

Publication number Publication date
JP2021054832A (ja) 2021-04-08
IL263431A (en) 2019-01-31
UA125436C2 (uk) 2022-03-09
CR20190002A (es) 2019-06-10
EP3463345A1 (en) 2019-04-10
EP3463345A4 (en) 2020-02-26
US11376239B2 (en) 2022-07-05
DK3463345T3 (da) 2023-01-09
RU2018146812A (ru) 2020-07-09
RU2759669C2 (ru) 2021-11-16
SG11201810793XA (en) 2018-12-28
CO2019000010A2 (es) 2019-05-21
KR102439911B1 (ko) 2022-09-05
SI3463345T1 (sl) 2023-02-28
ZA201900019B (en) 2023-04-26
BR112018074941A2 (pt) 2019-03-12
CN109890386B (zh) 2022-05-24
PH12018502549A1 (en) 2019-04-08
FI3463345T3 (fi) 2023-01-31
US10485788B2 (en) 2019-11-26
CN109890386A (zh) 2019-06-14
JP2019525948A (ja) 2019-09-12
EP3463345B1 (en) 2022-11-02
RU2018146812A3 (es) 2020-10-09
KR20190119507A (ko) 2019-10-22
AU2017275650A1 (en) 2019-01-17
PT3463345T (pt) 2023-01-06
US20200230108A1 (en) 2020-07-23
WO2017210538A1 (en) 2017-12-07
CL2018003421A1 (es) 2019-07-19
HUE060653T2 (hu) 2023-04-28
US20190105303A1 (en) 2019-04-11
MA45187A (fr) 2019-04-10
US20230044943A1 (en) 2023-02-09
PL3463345T3 (pl) 2023-02-06
CA3026361A1 (en) 2017-12-07
JP6805336B2 (ja) 2020-12-23
AU2017275650B2 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
PH12018502549A1 (en) Pharmaceutical combinations
ZA202202097B (en) Amino pyrimidine ssao inhibitors
NZ743881A (en) Fabs-in-tandem immunoglobulin and uses thereof
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MX2018015853A (es) Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
AR100215A1 (es) Conjugados de anticuerpo-fármaco anti-ptk7
PH12018501153A1 (en) Novel anti-claudin antibodies and methods of use
PH12018501043A1 (en) Site specific her2 antibody drug conjugates
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
EP3464560A4 (en) COMPOSITIONS AND METHODS FOR TUMOR VACCINATION AND IMMUNOTHERAPY WITH HER2 / NEU
MX2018010971A (es) Compuestos y métodos para modular la tirosina cinasa de bruton.
EP3895725A3 (en) A method for treating tumor by using recombinant interferon with changed spatial configuration
MX2016013704A (es) Conjugado farmaco-anticuerpo igf-1r y su uso para el tratamiento contra el cancer.
EP3459952A4 (en) PYRIMIDINE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF IN MEDICINE
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2018015172A (es) Metodos para tratar cancer pancreatico.
EP3304072A4 (en) Quantifying her2 protein for optimal cancer therapy
WO2017098051A3 (en) Combined preparations of pkm2 modulators and hmgb1
AU2018256669A1 (en) Combination therapy
PH12021550413A1 (en) Vitamin d pediatric dosage forms, methods of making and using
MX2017016346A (es) Metodos de tratamiento con taselisib.
WO2017083783A3 (en) Methods of cancer treatment
MX2020005344A (es) Compuestos de pirazolopiridinona.
MX2020005342A (es) Compuestos de pirazolopiridinona.